Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine alkaloids

This article was originally published in The Tan Sheet

Executive Summary

Comment period extension for submitting new usage data and scientific information on ephedrine alkaloid-containing supplements sought by House Government Reform Committee Chair Dan Burton (R-Ind.) in an April 27 letter to FDA. Burton says the 45-day comment period is "considerably inadequate" for public review of more than 270 newly released AERs and FDA's analyses of the reports, which were made public April 3 (1"The Tan Sheet" April 10, p. 6). The congressman requests the May 18 deadline be extended through Dec. 31, and advises FDA allow at least one month after close of the comment period before holding a public forum. Burton warns the committee could request GAO "conduct an additional review of the scientific basis for any future FDA proposals for these products"

You may also be interested in...



Ephedrine alkaloids

Comment period extended 45 days to July 3 for submitting new usage data and scientific evidence on ephedrine alkaloid-containing supplements, FDA says in a May 5 letter to House Government Reform Committee Chair Dan Burton (R-Ind.). Burton's requested extension of the May 18 deadline through December "is too long given the potential public health issues in question," the agency replies (1"The Tan Sheet" May 8, In Brief). In separate letters, several Texas congressmen and Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) also sought longer comment periods than granted by FDA. Scientific issues related to ephedrine alkaloid-containing supplements will be discussed at a public meeting in July; an upcoming Federal Register notice will provide additional details. A 30-day comment period will follow the forum

Ephedrine alkaloids

Comment period extended 45 days to July 3 for submitting new usage data and scientific evidence on ephedrine alkaloid-containing supplements, FDA says in a May 5 letter to House Government Reform Committee Chair Dan Burton (R-Ind.). Burton's requested extension of the May 18 deadline through December "is too long given the potential public health issues in question," the agency replies (1"The Tan Sheet" May 8, In Brief). In separate letters, several Texas congressmen and Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) also sought longer comment periods than granted by FDA. Scientific issues related to ephedrine alkaloid-containing supplements will be discussed at a public meeting in July; an upcoming Federal Register notice will provide additional details. A 30-day comment period will follow the forum

Ephedrine alkaloids

Comment period extended 45 days to July 3 for submitting new usage data and scientific evidence on ephedrine alkaloid-containing supplements, FDA says in a May 5 letter to House Government Reform Committee Chair Dan Burton (R-Ind.). Burton's requested extension of the May 18 deadline through December "is too long given the potential public health issues in question," the agency replies (1"The Tan Sheet" May 8, In Brief). In separate letters, several Texas congressmen and Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) also sought longer comment periods than granted by FDA. Scientific issues related to ephedrine alkaloid-containing supplements will be discussed at a public meeting in July; an upcoming Federal Register notice will provide additional details. A 30-day comment period will follow the forum

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel